Search

Your search keyword '"Robillard, Nelly"' showing total 312 results
Start Over Author "Robillard, Nelly"
312 results on '"Robillard, Nelly"'

2. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Author

Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G., Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C., Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, and Munshi, Nikhil

Published
2018
Full Text
View/download PDF

3. 90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study

Author

Chevallier, Patrice, Eugene, Thomas, Robillard, Nelly, Isnard, Françoise, Nicolini, Franck, Escoffre-Barbe, Martine, Huguet, Françoise, Hunault, Mathilde, Marcais, Antoine, Gaschet, Joelle, Cherel, Michel, Guillaume, Thierry, Delaunay, Jacques, Peterlin, Pierre, Eveillard, Marion, Thomas, Xavier, Ifrah, Norbert, Lapusan, Simona, Bodet-Milin, Caroline, Barbet, Jacques, Faivre-Chauvet, Alain, Ferrer, Ludovic, Bene, Marie C, Le Houerou, Claire, Goldenberg, David M, Wegener, William A, and Kraeber-Bodéré, Françoise

Published
2015
Full Text
View/download PDF

7. Photodynamic Therapy of Cancers

Author

Foultier, Marie Thérèse, Vonarx-Coinsman, Véronique, Morlet, Laurent, de Brito, Léonor Xavier, Robillard, Nelly, Patrice, Thierry, Jori, Giulio, editor, Pottier, Roy H., editor, Rodgers, Michael A. J., editor, and Truscott, T. George, editor

Published
1994
Full Text
View/download PDF

10. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Author

Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, Cymbalista, Florence, Cailleres, Sylvie, Damaj, Gandhi, Royer, Bruno, Gardembas, Martine, Dib, Mamoun, Truchan-Graczyk, Matgorzata, Hunault, Mathilde, Foussard, Charles, Corront, Bernadette, Parry, Anne, Orsini-Piocelle, Frédérique, Trouillier, Sébastien, Slama, Bohiane, Lepeu, Gérard, Zerazhi, Hacene, Boulat, Olivier, Azzedine, Ahmed, Araujo, Carla, Banos, Anne, Bauduer, Frédéric, Dutel, Jean-Luc, Ghomari, Kamel, Deconinck, Eric, Brion, Annie, Vuillier, Jacqueline, Saad, Alain, El Yamani, Abderrazak, Rodon, Philippe, Soubeyran, Pierre, Etienne, Gabriel, Dilhuydy, Marie-Sarah, Bouabdallah, Krimo, Leguay, Thibaut, Chouffi, Bachra, Pollet, Bertrand, Maakaroun, Abdallah, Guillerm, Gaëlle, Berthou, Christian, Cheron, Nathalie, ANDRÉ, Marc, Vilque, Jean Pierre, Fruchart, Christophe, Voillat, Laurent, Pica, Gian Matteo, Corm, Sélim, Micléa, Jean-Michel, Souleau, Bertrand, Molucon-Chabrot, Cécile, De Renzis, Benoit, Tournilhac, Olivier, Bay, Jacques-Olivier, Chaleteix, Carine, Guieze, Romain, Fleury, Joel, Precupanu, Cristina, Bouledroua, Selwa, Haiat, Stéphanie, Petitdidier, Charlotte, Dupuis, Jehan, Belhadj, Karim, Casasnovas, Olivier, Bastie, Jean-Noel, Ferrant, Emmanuelle, Gholam, Dany, Molina, Lysiane, Garban, Frédéric, Tiab, Mourad, Maisonneuve, Hervé, Villemagne, Bruno, Jacomy, Dominique, Besson, Caroline, Tertian, Gérard, Laribi, Kamel, Morel, Pierre, Cazin, Bruno, Moreau, Stéphane, Reminieras, Liliane, Rapp, Marie-José, Moreau, Philippe, Sebban, Catherine, Michallet, Anne-Sophie, Salles, Gilles, Broussais, Florence, Aurran-Schleinitz, Thérèse, Coso, Diane, Abarah, Wajed, Kulekci, Claire, Dorvaux, Véronique, Carassou, Philippe, Guibaud, Isabelle, Christian, Bernard, Graux, Carlos, Rossi, Jean-François, Quittet, Philippe, Dubois, Alain, Eisenmann, Jean-Claude, Morineau, Nadine, Mahé, Béatrice, Karsenti, Jean-Michel, Jourdan, Eric, Legouffe, Eric, Alexis-Vigier, Magda, Boulet, Jean-Michel, Aoudjhane, Malek, Thiéblemont, Catherine, Andreoli, Anna Lisa, Dreyfus, François, Choquet, Sylvain, Maloum, Karim, Merle-Béral, Hélène, Vekhoff, Anne, Decaudin, Didier, Brault, Philippe, Delarue, Richard, Janvier, Maud, Soussain, Carole, Vallantin, Xavier, Sanhes, Laurence, Dreyfus, Brigitte, Tomowiak, Cécile, Benramdane, Riad, Gonzalez, Hugo, Blaise-Brenna, Anne, Kolb, Brigitte, Delmer, Alain, Dauriac, Charles, Houot, Roch, Escoffre-Barbe, Martine, Lamy, Thierry, De Guibert, Sophie, Bernard, Marc, Grosbois, Bernard, Brehar, Oana, Morice, Patrick, Guyotat, Denis, Jaubert, Jérome, Portois, Christelle, Fornecker, Luc-Matthieu, Herbrecht, Raoul, Bilger, Karin, Ame, Shanti, Ysebaert, Loic, Godmer, Pascal, Jardel, Henry, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Saint-Etienne, CHU UCL Namur, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), CHU Grenoble, Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital Saint-Louis [AP-HP] (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Montpellier (UM), UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (MGD) Laboratoire de biologie clinique, UCL - (SLuc) Service d'hématologie, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)

Subjects
0301 basic medicine, Male, Cancer Research, Neoplasm, Residual, MESH: Immunotherapy, Chronic lymphocytic leukemia, Gastroenterology, MESH: Clinical Trials, Phase III as Topic, 0302 clinical medicine, Bone Marrow, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, MESH: Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Aged, education.field_of_study, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, MESH: Follow-Up Studies, Prognosis, 3. Good health, Fludarabine, Survival Rate, Leukemia, MESH: Antineoplastic Combined Chemotherapy Protocols, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, MESH: Vidarabine, MESH: Bone Marrow, Female, MESH: Rituximab, Immunotherapy, Rituximab, MESH: Clinical Trials, Phase II as Topic, Vidarabine, medicine.drug, medicine.medical_specialty, Cyclophosphamide, MESH: Survival Rate, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Chemoimmunotherapy, Internal medicine, medicine, Humans, education, Survival rate, MESH: Neoplasm, Residual, Aged, Retrospective Studies, MESH: Humans, business.industry, MESH: Cyclophosphamide, MESH: Retrospective Studies, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Male, body regions, 030104 developmental biology, Clinical Trials, Phase III as Topic, Bone marrow, business, MESH: Female, Follow-Up Studies
Abstract

International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD

Published
2020
Full Text
View/download PDF

13. Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma

Author

Debord, Camille, primary, Bourcier, Jessie, additional, Subiger, François, additional, Leclair, François, additional, Touzeau, Cyrille, additional, Gastinne, Thomas, additional, Moreau, Anne, additional, Theisen, Olivier, additional, Godon, Catherine, additional, Robillard, Nelly, additional, Le Bris, Yannick, additional, Béné, Marie C, additional, and Wuillème, Soraya, additional

Published
2020
Full Text
View/download PDF

17. Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Département de pharmacie, Solly, Françoise, Angelot-Delettre, Fanny, Ticchioni, Michel, Geneviève, Franck, Rambaud, Hubert, Baseggio, Lucile, Plesa, Adriana, Debliquis, Agathe, Garnache-Ottou, Francine, Roggy, Anne, Campos, Lydia, Aanei, Carmen, Rosenthal-Allieri, Alessandra, Georget, Marie-Thérèse, Lachot, Sébastien, Jacob, Marie-Christine, Robillard, Nelly, Wuilleme, Soraya, Andre-Kerneis, Elisabeth, Cornet, Edouard, Salaun, Véronique, Bennami, Hind, Lhoumeau, Anne-Catherine, Arnoulet, Christine, JACQMIN, Hugues, NEYMAN, Nicolas, Latger-Cannard, Véronique, Massin, Fredéric, Lainey, Elodie, Le Garff-Tavernier, Magali, Costopoulos, Myrto, Roussel, Mickael, Mayeur-Rousse, Caroline, Eischen, Alice, Raggeneau, Victoria, Derrieux, Coralie, Maurer, Maxime, Asnafi, Vahid, Trinquand, Amélie, Brouzes, Chantal, Lhermitte, Ludovic, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Département de pharmacie, Solly, Françoise, Angelot-Delettre, Fanny, Ticchioni, Michel, Geneviève, Franck, Rambaud, Hubert, Baseggio, Lucile, Plesa, Adriana, Debliquis, Agathe, Garnache-Ottou, Francine, Roggy, Anne, Campos, Lydia, Aanei, Carmen, Rosenthal-Allieri, Alessandra, Georget, Marie-Thérèse, Lachot, Sébastien, Jacob, Marie-Christine, Robillard, Nelly, Wuilleme, Soraya, Andre-Kerneis, Elisabeth, Cornet, Edouard, Salaun, Véronique, Bennami, Hind, Lhoumeau, Anne-Catherine, Arnoulet, Christine, JACQMIN, Hugues, NEYMAN, Nicolas, Latger-Cannard, Véronique, Massin, Fredéric, Lainey, Elodie, Le Garff-Tavernier, Magali, Costopoulos, Myrto, Roussel, Mickael, Mayeur-Rousse, Caroline, Eischen, Alice, Raggeneau, Victoria, Derrieux, Coralie, Maurer, Maxime, Asnafi, Vahid, Trinquand, Amélie, Brouzes, Chantal, and Lhermitte, Ludovic

Abstract

Flow cytometry is broadly used for the identification, characterization, and monitoring of hematological malignancies. However, the use of clinical flow cytometry is restricted by its lack of reproducibility across multiple centers. Since 2006, the EuroFlow consortium has been developing a standardized procedure detailing the whole process from instrument settings to data analysis. The FranceFlow group was created in 2010 with the intention to educate participating centers in France about the standardized instrument setting protocol (SOP) developed by the EuroFlow consortium and to organise several rounds of quality controls (QCs) in order to evaluate the feasibility of its application and its results. Here, we report the 5 year experience of the FranceFlow group and the results of the seven QCs of 23 instruments, involving up to 19 centers, in France and in Belgium. The FranceFlow group demonstrates that both the distribution and applicability of the SOP have been successful. Intercenter reproducibility was evaluated using both normal and pathological blood samples. Coefficients of variation (CVs) across the centers were <7% for the percentages of cell subsets and <30% for the median fluorescence intensities (MFIs) of the markers tested. Intracenter reproducibility provided similar results with CVs of <3% for the percentages of the majority of cell subsets, and CVs of <20% for the MFI values for the majority of markers. Altogether, the FranceFlow group show that the 19 participating labs might be considered as one unique laboratory with 23 identical flow cytometers able to reproduce identical results. Therefore, SOP significantly improves reproducibility of clinical flow in hematology and opens new avenues by providing a robust companion diagnostic tool for clinical trials in hematology. © 2019 International Society for Advancement of Cytometry.

Published
2019

23. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts

Author

Soulillou, Jean-Paul, Cantarovich, Diego, Le Mauff, Brigitte, Giral, Magali, Robillard, Nelly, Hourmant, Maryvonne, Hirn, Michel, and Jacques, Yannick

Subjects
Transplantation of organs, tissues, etc. -- Complications, Monoclonal antibodies -- Health aspects, Graft rejection -- Prevention, Transplantation immunology -- Research, Immunosuppressive agents -- Evaluation, Immunosuppression -- Health aspects
Abstract

After patients receive kidney transplants, they either receive immunosuppressive drugs such as cyclosporine and steroids, or an agent such as polyclonal antilymphocyte serum (a different immunosuppressant), followed by cyclosporine and steroids two weeks later. An advantage of the latter regimen is that it allows the graft to recover from ischemia (decreased blood supply) during the time when it is especially sensitive to the toxic effects of cyclosporine. A monoclonal antibody has been developed that selectively inactivates only those lymphocytes that act against donor antigens, and this could be useful as an alternative to antilymphocyte serum, since it is more specific and does not inactivate all T cells. The substance, 33B3.1, acts by interfering with binding of interleukin-2 to its receptor on the T cell, thereby preventing proliferation of T cells. Its effectiveness was tested in 100 patients receiving their first renal transplants, half of whom received 33B3.1, and half of whom received antithymocyte globulin in a randomized study. Other medications were also administered. Patients were followed-up 5 to 22 months. Rejection was assessed clinically and by biopsy, when necessary, in both groups. The severity of infection with cytomegalovirus was noted. Results showed that the new antibody was tolerated better than antithymocyte globulin, a large percentage of whose recipients discontinued treatment during the first 14 days. One patient could not tolerate 33B3.1. Differences between the groups in subsets of T cells were found, such that antithymocyte globulin patients had greater drops in their CD2-, CD3-, CD4-, and CD8-positive cell counts. There were more rejection episodes in the 33B3.1 group (six) than the antithymocyte group (one), although the difference was not statistically significant. There were no group differences in patient (96 percent) or graft (85 percent) survival. Fewer infections were noted in the 33B3.1 group, including urinary tract infections, but the incidence of cytomegalovirus was about the same in both groups. Overall, it appears that the interleukin-2 receptor is an appropriate target for an immunosuppressive agent, and that 33B3.1 is an effective compound in this regard. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

25. Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation

Author

LE Bris, Yannick, primary, Guillaume, Thierry, additional, Debord, Camille, additional, Peterlin, Pierre, additional, Wuilleme, Soraya, additional, Bressollette, Céline, additional, Le Bourgeois, Amandine, additional, Garnier, Alice, additional, Fantou, Aurélie, additional, Audrain, Marie, additional, Ménard, Audrey, additional, Robillard, Nelly, additional, Eveillard, Marion, additional, Le Gouill, Steven, additional, Imbert, Berthe Marie, additional, Bene, Marie C, additional, and Chevallier, Patrice, additional

Published
2019
Full Text
View/download PDF

26. FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia

Author

Peterlin, Pierre, primary, Gaschet, Joelle, additional, Guillaume, Thierry, additional, Garnier, Alice, additional, Eveillard, Marion, additional, Le Bourgeois, Amandine, additional, Cherel, Michel, additional, Debord, Camille, additional, Le Bris, Yannick, additional, Theisen, Olivier, additional, Mahé, Béatrice, additional, Dubruille, Viviane, additional, Godon, Catherine, additional, Robillard, Nelly, additional, Wuilleme, Soraya, additional, Touzeau, Cyrille, additional, Gastinne, Thomas, additional, Blin, Nicolas, additional, Lok, Anne, additional, Bonnet, Antoine, additional, Le Gouill, Steven, additional, Moreau, Philippe, additional, Béné, Marie-C., additional, and Chevallier, Patrice, additional

Published
2019
Full Text
View/download PDF

27. Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience

Author

Solly, Françoise, primary, Angelot‐Delettre, Fanny, additional, Ticchioni, Michel, additional, Geneviève, Franck, additional, Rambaud, Hubert, additional, Baseggio, Lucile, additional, Plesa, Adriana, additional, Debliquis, Agathe, additional, Garnache‐Ottou, Francine, additional, Roggy, Anne, additional, Campos, Lydia, additional, Aanei, Carmen, additional, Rosenthal‐Allieri, Alessandra, additional, Georget, Marie‐Thérèse, additional, Lachot, Sébastien, additional, Jacob, Marie‐Christine, additional, Robillard, Nelly, additional, Wuilleme, Soraya, additional, Andre‐Kerneis, Elisabeth, additional, Cornet, Edouard, additional, Salaun, Véronique, additional, Bennami, Hind, additional, Lhoumeau, Anne‐Catherine, additional, Arnoulet, Christine, additional, Jacqmin, Hugues, additional, Neyman, Nicolas, additional, Latger‐Cannard, Véronique, additional, Massin, Fredéric, additional, Lainey, Elodie, additional, Le Garff‐Tavernier, Magali, additional, Costopoulos, Myrto, additional, Roussel, Mickael, additional, Mayeur‐Rousse, Caroline, additional, Eischen, Alice, additional, Raggeneau, Victoria, additional, Derrieux, Coralie, additional, Maurer, Maxime, additional, Asnafi, Vahid, additional, Trinquand, Amélie, additional, Brouzes, Chantal, additional, and Lhermitte, Ludovic, additional

Published
2019
Full Text
View/download PDF

28. FLT3 ligand plasma levels in acute myeloid leukemia

Author

Peterlin, Pierre, primary, Gaschet, Joelle, additional, Guillaume, Thierry, additional, Garnier, Alice, additional, Eveillard, Marion, additional, Le Bourgeois, Amandine, additional, Cherel, Michel, additional, Debord, Camille, additional, Le Bris, Yannick, additional, Theisen, Olivier, additional, Mahé, Béatrice, additional, Dubruille, Viviane, additional, Godon, Catherine, additional, Robillard, Nelly, additional, Wuilleme, Soraya, additional, Touzeau, Cyrille, additional, Gastinne, Thomas, additional, Blin, Nicolas, additional, Lok, Anne, additional, Bonnet, Antoine, additional, Le Gouill, Steven, additional, Moreau, Philippe, additional, Béné, Marie-C, additional, and Chevallier, Patrice, additional

Published
2019
Full Text
View/download PDF

30. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G, Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C, Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, Munshi, Nikhil, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G, Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C, Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, and Munshi, Nikhil

Abstract

The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate end point in clinical trials. We assessed the prognostic value of MRD, measured during maintenance therapy by next-generation sequencing (NGS). MRD negativity was defined as the absence of tumor plasma cell within 1 000 000 bone marrow cells (<10). Data were analyzed from a recent clinical trial that evaluated the role of transplantation in newly diagnosed myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD). MRD negativity was achieved at least once during maintenance in 127 patients (25%). At the start of maintenance therapy, MRD was a strong prognostic factor for both progression-free survival (adjusted hazard ratio, 0.22; 95% confidence interval, 0.15-0.34; < .001) and overall survival (adjusted hazard ratio, 0.24; 95% confidence interval, 0.11-0.54; = .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.

Published
2018

31. DNA or cell kinetics flow cytometry analysis of 33 small gastrointestinal cancers treated by photodynamic therapy

Author

Foultier, Marie-Therese, Vonarx-Coinsman, Veronique, Brito, Leonor Xavier de, Morlet, Laurent, Robillard, Nelly, and Patrice, Thierry

Subjects
Photochemotherapy -- Evaluation, Gastrointestinal cancer -- Care and treatment, Porphyrins -- Health aspects, Health
Abstract

Background. Photodynamic therapy (PDT) mediated by hematoporphyrin derivative (HPD) is a new treatment for cancers of small volume undergoing Phase II or III clinical trials in various medical fields. However, there is a lack of prognostic criteria of efficacy as in other cancer treatment. Methods. Cell DNA content or cell kinetics throughout the cell cycle were analyzed by flow cytometry and propidium iodide staining before and after HPD-PDT in 33 patients with Tis or T1 cancers of the gastrointestinal tract. The authors compared results in near-diploid cancers with those obtained in normal corresponding tissue. Results. Complete local tumor destruction and negative histologic findings (complete response [CRI) were observed in 17 of 33 patients during a period averaging 15.7 months. Flow cytometry DNA analysis was feasible in 32 patients. Aneuploidy, found in 15 of the 32 indicated a poor prognosis because 5 of 15 patients with aneuploid tumors were classified as having CR, compared with 12 of 17 patients with near-diploid tumors (P < 0.05). Changes in ploidy after PDT in 11 patients consisted of a reduction in the number of aneuploid peaks in 8 patients and the appearance of one aneuploid peak in 3 patients. Percentages of cells in SG2M phase in near-diploid tumors differed from those observed in control subjects for adenocarcinomas, and there was no significant decrease after HPD-PDT. There was no correlation between the decrease of SG2M cells and the response to HPD-PDT. Conclusion. Results obtained with PDT in this series of patients confirm previously published findings. Changes occurring in the ploidy of PDT-treated patients demonstrate that PDT acts directly on cancer cells in humans and not only on tumor vasculature. However, response to PDT varies from one cell population to another. The appearance of aneuploid populations after PDT suggests that destruction of sensitive cell populations allows the growth of aneuploid clones that initially are not detectable by flow cytometry. Cancer 1994; 73:1595-1607. Key words: hematoporphyrin derivative, photodynamic therapy, gastrointestinal cancers, DNA, flow cytometry.

Published
1994

32. Multicentric Standardized Flow Cytometry Routine Assessment of Patients With Sepsis to Predict Clinical Worsening

Author

Daix, Thomas, primary, Guerin, Estelle, additional, Tavernier, Elsa, additional, Mercier, Emmanuelle, additional, Gissot, Valérie, additional, Hérault, Olivier, additional, Mira, Jean-Paul, additional, Dumas, Florence, additional, Chapuis, Nicolas, additional, Guitton, Christophe, additional, Béné, Marie C., additional, Quenot, Jean-Pierre, additional, Tissier, Cindy, additional, Guy, Julien, additional, Piton, Gaël, additional, Roggy, Anne, additional, Muller, Grégoire, additional, Legac, Éric, additional, de Prost, Nicolas, additional, Khellaf, Mehdi, additional, Wagner-Ballon, Orianne, additional, Coudroy, Rémi, additional, Dindinaud, Elodie, additional, Uhel, Fabrice, additional, Roussel, Mikaël, additional, Lafon, Thomas, additional, Jeannet, Robin, additional, Vargas, Frédéric, additional, Fleureau, Catherine, additional, Roux, Mickaël, additional, Allou, Kaoutar, additional, Vignon, Philippe, additional, Feuillard, Jean, additional, François, Bruno, additional, Di Vittorio, Adollës, additional, Lachot, Sébastien, additional, Georget, Marie-Thérèse, additional, Hanna, Joelle, additional, Bretonnière, Cédric, additional, Zambon, Olivier, additional, Nicolet, Laurent, additional, Brule, Noëlle, additional, Debord, Camille, additional, Le Bris, Yannick, additional, Robillard, Nelly, additional, Dargent, Auguste, additional, Bretagnol, Anne, additional, Mathonnet, Armelle, additional, Boulain, Thierry, additional, Barbier, François, additional, Benzekri, Dalila, additional, Runge, Isabelle, additional, Kamel, Toufik, additional, Cecchini, Jérôme, additional, Bouyer, Sabrina, additional, Robert, René, additional, and Ouattara, Alexandre, additional

Published
2018
Full Text
View/download PDF

33. CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms

Author

Debord, Camille, primary, Robillard, Nelly, additional, Theisen, Olivier, additional, Gastinne, Thomas, additional, Godmer, Pascal, additional, Graveleau, Julie, additional, Le Gouill, Steven, additional, Luycx, Odile, additional, Tiab, Mourad, additional, Loirat, Marion, additional, Lestang, Elsa, additional, Wuillème, Soraya, additional, Godon, Catherine, additional, Eveillard, Marion, additional, and Béné, Marie Christine, additional

Published
2018
Full Text
View/download PDF

35. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Author

Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, and Cymbalista, Florence

Abstract

Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10−5) MRD assessment using flow cytometry, in blood (N= 401) and bone marrow (N= 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD < 0.01% to MRD ≥ 0.01% increased the proportion of cases with positive MRD in blood by 39% and in bone marrow by 27%. Compared to low-level positive MRD < 0.01%, undetectable MRD was associated with significantly longer progression-free survival (PFS) when using blood (72.2 versus 42.7 months; hazard ratio 0.40, p= 0.0003), but not when using bone marrow. Upon further stratification, positive blood MRD at any level, compared to undetectable blood MRD, was associated with shorter PFS irrespective of clinical complete or partial remission, and a lower 5-year PFS rate irrespective of IGHV-mutated or -unmutated status (all p< 0.05). In conclusion, high-sensitivity (0.0007%) MRD assessment in blood yielded additional prognostic information beyond the current standard sensitivity (0.01%). Our approach provides a model for future determination of the optimal MRD investigative strategy for any regimen.

Published
2021
Full Text
View/download PDF

36. Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia

Author

Chevallier, Patrice, primary, Chantepie, Sylvain, additional, Huguet, Francoise, additional, Raffoux, Emmanuel, additional, Thomas, Xavier, additional, Leguay, Thibaut, additional, Marchand, Tony, additional, Isnard, Francoise, additional, Charbonnier, Aude, additional, Maury, Sébastien, additional, Gallego-Hernanz, Maria-Pilar, additional, Robillard, Nelly, additional, Guillaume, Thierry, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Rialland, Fanny, additional, Le Houerou, Claire, additional, Goldenberg, David M., additional, Wegener, William A., additional, Béné, Marie-C., additional, and Dombret, Hervé, additional

Published
2017
Full Text
View/download PDF

37. ⁹⁰Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study

Author

Chevallier, Patrice, Eugène, Thomas, Robillard, Nelly, Isnard, Françoise, Nicolini, Franck, Escoffre Barbe, Martine, Huguet, Françoise, Hunault, Mathilde, Marçais, Antoine, Gaschet, Joëlle, Cherel, Michel, Guillaume, Thierry, Delaunay, Jacques, Peterlin, Pierre, Eveillard, Marion, Thomas, Xavier, Ifrah, Norbert, Lapusan, Simona, Bodet-Milin, Caroline, Barbet, Jacques, Faivre-Chauvet, Alain, Ferrer, Ludovic, Bene, Marie, Le Houerou, Claire, Goldenberg, David, Wegener, William, Kraeber-Bodéré, Françoise, Bernardo, Elizabeth, Service d'Hématologie Clinique [Nantes], Hôpital Hôtel Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Médecine Nucléaire [Nantes], Hôpital Laennec, Département d'hématologie et de biologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Laboratoire d'Hématologie et d'Immunologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Pontchaillou [Rennes], Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'hématologie [Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Immunomedics Inc. [Morris Plains, NJ, USA], Laboratoire d'Hematologie [CHU Pontchaillou, Rennes] (Pôle de Biologie), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], Service d'Hématologie [IUCT Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience; Background: Prognosis of patients with relapsed or refractory acute lymphoblastic leukaemia is poor and new treatments are needed. We aimed to assess the feasibility, tolerability, dosimetry, and efficacy of yttrium-90-labelled anti-CD22 epratuzumab tetraxetan ((90)Y-DOTA-epratuzumab) radioimmunotherapy in refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia in a standard 3 + 3 phase 1 study.Methods: Adults (≥18 years) with relapsed or refractory B-cell acute lymphoblastic leukaemia (with CD22 expression on at least 70% of blast cells) were enrolled at six centres in France. Patients received one cycle of (90)Y-DOTA-epratuzumab on days 1 and 8 (give or take 2 days) successively at one of four dose levels: 2·5 mCi/m(2) (92·5 MBq/m(2); level 1), 5·0 mCi/m(2) (185 MBq/m(2); level 2), 7·5 mCi/m(2) (277·5 MBq/m(2); level 3), and 10·0 mCi/m(2) (370 MBq/m(2); level 4). The primary objective was to identify the maximum tolerated dose of (90)Y-DOTA-epratuzumab. We assessed safety during infusions and regularly after radioimmunotherapy over a 6-month period. Analyses included only patients who received radioimmunotherapy. The trial is closed to inclusion and is registered at ClinicalTrials.gov, NCT01354457.Findings: Between Aug 25, 2011, and June 11, 2014, 17 patients (median age 62 years; range 27-77) were treated (five at level 1, three at level 2, three at level 3, and six at level 4). Radioimmunotherapy infusion was overall well tolerated. One dose-limiting toxic effect (aplasia lasting 8 weeks) occurred at level 4, but the maximum tolerated dose was not reached. The most common grade 3-4 adverse events were pancytopenia (one patient at level 2, one at level 3, and six at level 4) and infections (three at level 1, one at level 2, and five at level 4).Interpretation: (90)Y-DOTA-epratuzumab radioimmunotherapy is well tolerated. We recommend the dose of 2 × 10·0 mCi/m(2) 1 week apart per cycle for phase 2 studies.Funding: Immunomedics and Direction de la Recherche Clinique of Nantes.

Published
2015
Full Text
View/download PDF

38. CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy

Author

Eveillard, Marion, primary, Floc'h, Victor, additional, Robillard, Nelly, additional, Debord, Camille, additional, Wuilleme, Soraya, additional, Garand, Richard, additional, Rialland, Fanny, additional, Thomas, Caroline, additional, Peterlin, Pierre, additional, Guillaume, Thierry, additional, Moreau, Philippe, additional, Chevallier, Patrice, additional, and Bene, Marie C, additional

Published
2016
Full Text
View/download PDF

39. In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)

Author

Clemenceau, Beatrice, primary, Guillaume, Thierry, additional, Robillard, Nelly, additional, Vivien, Regine, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Bene, Marie-Christine, additional, Vié, Henri, additional, and Chevallier, Patrice, additional

Published
2016
Full Text
View/download PDF

40. Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

Author

Chevallier, Patrice, primary, Chantepie, Sylvain, additional, Huguet, Françoise, additional, Raffoux, Emmanuel, additional, Thomas, Xavier, additional, Leguay, Thibaut, additional, Marchand, Tony, additional, Isnard, Francoise, additional, Charbonnier, Aude, additional, Maury, Sebastien, additional, Gallego-Hernanz, Maria-Pilar, additional, Robillard, Nelly, additional, Guillaume, Thierry, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Rialland, Fanny, additional, Le Houerou, Claire, additional, Goldenberg, David M, additional, Wegener, William, additional, Bene, Marie C, additional, and Dombret, Herve, additional

Published
2016
Full Text
View/download PDF

41. A new mutation of ANO6 in two familial cases of Scott syndrome

Author

Boisseau, Pierre, primary, Bene, Marie C., additional, Besnard, Thomas, additional, Pachchek, Sinthuja, additional, Giraud, Mathilde, additional, Talarmain, Patricia, additional, Robillard, Nelly, additional, Gourlaouen, Marie A., additional, Bezieau, Stéphane, additional, and Fouassier, Marc, additional

Published
2016
Full Text
View/download PDF

43. Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

Author

Avet-Loiseau, Herve, primary, Corre, Jill, additional, Lauwers-Cances, Valerie, additional, Chretien, Marie-Lorraine, additional, Robillard, Nelly, additional, Leleu, Xavier, additional, Hulin, Cyrille, additional, Gentil, Catherine, additional, Arnulf, Bertrand, additional, Belhadj, Karim, additional, Brechignac, Sabine, additional, Garderet, Laurent, additional, Karlin, Lionel, additional, Marit, Gerald, additional, Benboubker, Lotfi, additional, Orsini-Piocelle, Frederique, additional, Royer, Bruno, additional, Drenou, Bernard, additional, Tiab, Mourad, additional, Lamy, Thierry, additional, MACRO, Margaret, additional, Richardson, Paul G., additional, Anderson, Kenneth C, additional, Faham, Malek, additional, Facon, Thierry, additional, Moreau, Philippe, additional, Attal, Michel, additional, and Munshi, Nikhil C., additional

Published
2015
Full Text
View/download PDF

44. Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome

Author

Le Bris, Yannick, primary, Guillaume, Thierry, additional, Iliaquer, Marina, additional, Martin, Jerome, additional, Peterlin, Pierre, additional, Menard, Audrey, additional, Eveillard, Marion, additional, Wuilleme, Soraya, additional, Robillard, Nelly, additional, Delaunay, Jacques, additional, Mohty, Mohamad, additional, Garnier, Alice, additional, Moreau, Philippe, additional, Bene, Marie C, additional, and Chevallier, Patrice, additional

Published
2015
Full Text
View/download PDF

45. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia

Author

Eveillard, Marion, primary, Robillard, Nelly, additional, Arnoux, Isabelle, additional, Garand, Richard, additional, Rialland, Fanny, additional, Thomas, Caroline, additional, Strullu, Marion, additional, Michel, Gérard, additional, Béné, Marie C., additional, Fossat, Chantal, additional, and Loosveld, Marie, additional

Published
2015
Full Text
View/download PDF

46. 90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study

Author

Chevallier, Patrice, primary, Eugene, Thomas, additional, Robillard, Nelly, additional, Isnard, Françoise, additional, Nicolini, Franck, additional, Escoffre-Barbe, Martine, additional, Huguet, Françoise, additional, Hunault, Mathilde, additional, Marcais, Antoine, additional, Gaschet, Joelle, additional, Cherel, Michel, additional, Guillaume, Thierry, additional, Delaunay, Jacques, additional, Peterlin, Pierre, additional, Eveillard, Marion, additional, Thomas, Xavier, additional, Ifrah, Norbert, additional, Lapusan, Simona, additional, Bodet-Milin, Caroline, additional, Barbet, Jacques, additional, Faivre-Chauvet, Alain, additional, Ferrer, Ludovic, additional, Bene, Marie C, additional, Le Houerou, Claire, additional, Goldenberg, David M, additional, Wegener, William A, additional, and Kraeber-Bodéré, Françoise, additional

Published
2015
Full Text
View/download PDF

47. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.

Author

Eveillard, Marion, Robillard, Nelly, Arnoux, Isabelle, Garand, Richard, Rialland, Fanny, Thomas, Caroline, Strullu, Marion, Michel, Gérard, Béné, Marie C., Fossat, Chantal, and Loosveld, Marie

Subjects
LYMPHOBLASTIC leukemia diagnosis, CARCINOGENESIS, BONE marrow, FLOW cytometry, LYMPHOBLASTIC leukemia
Abstract

The early persistence of minimal residual disease (MRD) is considered a poor prognostic factor indicative of chemoresistance in acute lymphoblastic leukemia. In French children, chemosensitivity is assessed at day 21 post-induction by cytomorphology. Here, it was investigated whether a more precise evaluation could be obtained at this time point with multiparameter flow cytometry (MFC). This study enrolled 123 children with de novo acute lymphoblastic leukemia. MRD0 was investigated at day 21 in MFC with a combination of antibodies based on the immunophenotype of diagnosis. It was also evaluated at day 35 by immunoglobulin/T-cell receptor quantitative real-time polymerase chain reaction (MRD1). Three risk groups could be delineated based on MRD0. Patients with MFC/MRD0 levels >10-2 (n = 25) were considered high risk, those with levels between 10-2 and 10-4 (n = 46) intermediate risk, and those <10-4 (n = 50) low risk. Overall survival (p = 0.048) and event-free survival (EFS, p = 0.00017) were significantly different between these three groups. EFS of the 14 corticoresistant patients strongly depended on their MRD0 level (p = 0.004). Similarly, both EFS (p = 0.0004) and overall survival (p = 0.02) were significantly different in the 109 chemosensitive patients, according to MRD0 levels. MRD0 and MRD1 levels, compared with 112 patients, were consistent (-/- or +/+) in 57.2% of the cases. Both MRD0+/MRD1+ and MRD0+/MRD1- patients had a significantly worse EFS (p = 0.0001) than those with undetectable MRD at both MRD0 and MRD1. This study confirms the usefulness and superiority of an early point of MRD detection by MFC. In addition, MRD0 in MFC identifies a subgroup of patients with poorer prognosis (MRD0+/MRD1-). Copyright © 2015 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

48. Phase 1 Dose-Escalation Study of 90yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Author

Chevallier, Patrice, primary, Eugene, Thomas, additional, Robillard, Nelly, additional, Isnard, Françoise, additional, Nicolini, Franck E, additional, Escoffre-Barbe, Martine, additional, Huguet, Françoise, additional, Hunault, Mathilde, additional, Marcais, Antoine, additional, Guillaume, Thierry, additional, Delaunay, Jacques, additional, Peterlin, Pierre, additional, Thomas, Xavier, additional, Ifrah, Norbert, additional, Lapusan, Simona, additional, bodet-Milin, Caroline, additional, faivre Chauvet, Alain, additional, Le Houerou, Claire, additional, Goldenberg, David M, additional, Wegener, William A, additional, and Kraeber-Bodere, Françoise, additional

Published
2014
Full Text
View/download PDF

49. Value of Day 21 Flow Cytometry Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia (ALL) for Early Identification of Good Responders

Author

Eveillard, Marion, primary, Robillard, Nelly, additional, Garand, Richard, additional, Rialland, Fanny, additional, Blin, Nicolas, additional, Strullu, Marion, additional, Thomas, Caroline, additional, Fossat, Chantal, additional, Arnoux, Isabelle, additional, Bene, Marie-Christine, additional, and Loosveld, Marie, additional

Published
2014
Full Text
View/download PDF

50. Chemoimmunotherapy Combining Vincristine, Dexamethasone and Epratuzumab (hLL2) As Salvage Regimen for Older Relapsed/Refractory, CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) Patients: Results of the French Non-Intensive Phase 2 Prospective Cheprall Study

Author

Chevallier, Patrice, primary, Huguet, Françoise, additional, Raffoux, Emmanuel, additional, Etienne, Anne, additional, Leguay, Thibaut, additional, Isnard, Françoise, additional, Robillard, Nelly, additional, Guillaume, Thierry, additional, Delaunay, Jacques, additional, Peterlin, Pierre, additional, Charbonnier, Aude, additional, Pigneux, Arnaud, additional, Le Houerou, Claire, additional, Goldenberg, David M, additional, Wegener, William A, additional, and Dombret, Hervé, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results